Trial Profile
Multi-center, open-label safety study of lubiprostone for the treatment of chronic idiopathic constipation (CIC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Sucampo Pharmaceuticals
- 24 May 2016 New trial record